RA Capital Management’s Design Therapeutics DSGN Stock Holding History

RA Capital Management’s Portfolio DSGN Stock Details DSGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-2,972,973	Closed	-$31.6M	–	86
2026 Q1	$31.6M	Buy	2,972,973 +1,511,592	+103%	+$15.3M	0.34%	44
2025 Q4	$13.7M	Buy	1,461,381 +985,682	+207%	+$7.72M	0.14%	56
2025 Q3	$3.58M	Buy	+475,699	New	+$2.38M	0.04%	64
2023 Q3	–	Sell	-2,971,231	Closed	-$18.7M	–	67
2023 Q2	$18.7M	Hold	2,971,231	–	–	0.35%	45
2023 Q1	$17.1M	Hold	2,971,231	–	–	0.39%	48
2022 Q4	$30.5M	Buy	2,971,231 +198,000	+7%	+$2.68M	0.62%	40
2022 Q3	$46.4M	Buy	2,773,231 +586,595	+27%	+$11.7M	0.99%	34
2022 Q2	$30.6M	Hold	2,186,636	–	–	0.82%	36
2022 Q1	$35.3M	Hold	2,186,636	–	–	0.77%	41
2021 Q4	$46.8M	Hold	2,186,636	–	–	0.83%	35
2021 Q3	$32.1M	Hold	2,186,636	–	–	0.45%	50
2021 Q2	$43.5M	Hold	2,186,636	–	–	0.7%	47
2021 Q1	$65.4M	Buy	+2,186,636	New	+$73.8M	0.99%	33

Other funds holding DSGN

SOCM

SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

TECP

Trails Edge Capital Partners Atlanta, Georgia $630M AUM

FLSM

Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

RA Capital Management's DSGN Position: Q2 2026 in Review

RA Capital Management sold out of Design Therapeutics (DSGN) in Q2 2026, closing a stake of 2,972,973 shares — an estimated $31.6M sold.

RA Capital Management first reported a position in DSGN in Q1 2021 and held it in 13 quarters. The position peaked at $65.4M in Q1 2021. 137 funds tracked by Wall St. Rank hold DSGN as of Q2 2026.

RA Capital Management reported no remaining Design Therapeutics position as of Q2 2026 after selling out during the quarter.
RA Capital Management sold 2,972,973 Design Therapeutics shares in Q2 2026, an estimated $31.6M.
RA Capital Management first reported a position in Design Therapeutics in Q1 2021 and held it in 13 quarters.
RA Capital Management's Design Therapeutics position peaked at $65.4M in Q1 2021.
137 funds tracked by Wall St. Rank held Design Therapeutics as of Q2 2026.

Based on RA Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.